NASDAQ: HALO

Halozyme Therapeutics (HALO) Stock Analysis & Forecast

Nov 13 close

$100.27−0.40 (−0.4%)

Gekko Brief

AI summaryNov 9 close

Halozyme's week centers on Q3 2026 results that beat Street forecasts, with non-GAAP EPS of $2.39 and revenue up 39.1% year over year, driven by record ENHANZE royalty income of $341 million. The company raised its full-year 2026 guidance on the back of royalty growth and newer subcutaneous drug launches, yet the stock fell over 6% in after-hours trading and then dropped over 13% after Leerink Partners downgraded the name, with analysts noting results only marginally exceeded forecasts. Separately, Halozyme reaffirmed that the Medicare Drug Price Negotiation Program's final rule is expected to have zero to minimal impact on royalty revenue through at least 2035, and the FDA approved RYBREVANT FASPRO, co-formulated with Halozyme's ENHANZE technology, for advanced head and neck cancer.

Shares closed at $102.92, down 0.7%, sitting below the 50-day average of $115.14 but above the 200-day average of $84.83. The GekkoIndex reads 69.9, placing HALO in the Accumulation zone. Gekko Fair Value stands at $105.59, putting the stock about 2.5% below that level.

The next earnings date is 16 February 2027, 98 days out and beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality skews negative, with the next 20 trading days averaging -4.3% over 5 years and rising in only 2 of them, which bears watching given the stock's typical 8.7% move over a similar span.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Halozyme Therapeutics price vs fair value

$106.84$100.27Nov ’25May ’26Nov ’26
Close $100.27200-day averageGekko Fair Value $106.84

Halozyme Therapeutics quick facts

Market cap
$11.43B
P/E ratio
25.2
Forward P/E
11.2
EPS, TTM
$4.00
Revenue, TTM
$1.80B
Profit margin
26.9%
Dividend yield
—
Beta
0.90
Volume
2.28M avg 2.33M
1-year return
+42.0%
Typical daily move
±5%
Typical 20-day move
±8.7%
50-day average
$114.56
200-day average
$85.43
Next earnings
Feb 16 after close
Shares outstanding
114.0M
52-week range
$61.23$134.00

Halozyme Therapeutics swing-trade checklist

Halozyme Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $100.27 sits between the 50-day ($114.56) and 200-day ($85.43) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    70.2, Buying

    Reading 70.2 is in the Buying zone.

    See the GekkoIndex
  • Fair valuesupportive

    6.1% below

    Price is 6.1% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 93 days

    Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −4.6% on average

    From this point in the calendar, the next 20 trading days averaged −4.6% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Halozyme Therapeutics stock chart and price history

Halozyme Therapeutics closed at $100.27 on Nov 13, 2026, +42.0% over the past year, inside a 52-week range of $61.23 to $134.00.

Close50-day average200-day averageVolume
Halozyme Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$60$80$120DecJan 2026FebMarAprMayJunJulAugSepOctNov100.27

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−17.5%
3 months
−2.7%
6 months
+49.4%
1 year
+42.0%
The full HALO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HALO in Gekko

Follow Halozyme Therapeutics through every session

Put HALO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track HALO in GekkoFree for 7 days. No credit card required.

About Halozyme Therapeutics

Halozyme Therapeutics develops technology that helps deliver injectable medicines beneath the skin rather than through longer infusions. Its central offering, ENHANZE, is built around a patented enzyme called rHuPH20 that makes it easier for biologics, antibodies, smaller drug compounds and fluids to be absorbed subcutaneously. The company is also known for Hylenex recombinant, an rHuPH20-based product used to support subcutaneous fluid delivery for hydration and to assist dispersion and absorption of other injected drugs.

Beyond its own products, Halozyme licenses its delivery platform to other pharmaceutical makers, whose treatments for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia and immunodeficiency disorders incorporate the technology. Its pipeline work extends to investigational treatments for cancers, multiple sclerosis, myeloma and autoimmune disease, developed through partnerships with companies including Roche, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics, as well as with research bodies working on HIV treatment and prevention.

Halozyme Therapeutics is headquartered in San Diego, California, with operations across the United States, Switzerland, Ireland, Belgium, Japan and other markets, and was founded in 1998. Its shares are listed on the NASDAQ under the ticker HALO.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
halozyme.com

Halozyme Therapeutics GekkoIndex: the smart money zone

Halozyme Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.2, in the Buying zone, up 3.7 points over five sessions.

010070.2Buying

Up 3.7 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying (current zone)30+2.9%+4.0%+11.8%+13.0%
Accumulation179+1.1%+2.9%+4.3%+13.1%
Neutral406+0.9%+1.8%+3.8%+9.5%
Distribution83+1.6%+2.0%+4.3%+7.0%
Selling4Too few readings yet

Average HALO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.

Buying zone: Smart money likely accumulating heavily. About the five zones →

See every daily GekkoIndex reading plotted over the HALO price, zone by zone.Track HALO in Gekko

Is Halozyme Therapeutics stock overvalued? Gekko Fair Value

Halozyme Therapeutics trades 6.1% below Gekko Fair Value of $106.84, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Halozyme Therapeutics shares are worth, recalculated every trading day.

$106.84

Gekko Fair Value, Nov 14, 2026

6.1% Undervalued

At the end of Aug 2026 the price was 7.1% above the estimate.

Gekko Fair ValueShare price, month end
$107$100Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open HALO in Gekko

Halozyme Therapeutics insider and Congress trading

No open-market insider purchases were filed for Halozyme Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for HALO in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every HALO insider filing, plotted on the chart in Gekko.Open HALO in Gekko

Congress trades last 90 days

No trades in HALO were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for HALO, plotted on the chart in Gekko.Open HALO in Gekko

Buybacks

Halozyme Therapeutics has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$67.27M
As a share of market cap
0.59%

From company filings.

Halozyme Therapeutics earnings: next date and track record

Halozyme Therapeutics reports on Feb 16, 2027, after the close (93 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±10.9%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−0.9%Feb ’25+15.7%May ’25+3.9%Aug ’25+4.4%Nov ’25−7.8%Feb ’26+10.6%May ’26+23.4%Aug ’26−20.5%Nov ’26

Last earnings call, Nov 5, 2026 AI summary

What they said
Halozyme reported record Q3 2026 results with total revenue up 39% YoY to $493M, driven by royalty revenue rising 44% to $341M. Adjusted EBITDA reached $336M at a 68% margin. Three partners expanded ENHANZE agreements adding 4 new targets, and three programs from Pfizer, Incyte, and argenx entered Phase I. OCREVUS ZUNOVO reached 56,000 patients globally with 20%+ conversion, while OPDIVO Qvantig achieved 17% IV-to-SC conversion.
Guidance
Halozyme raised its full year 2026 financial guidance based on Q3 strength. Management cited continued royalty revenue diversification and growth from both established and newly launched ENHANZE-enabled products as drivers, targeting 13 ENHANZE programs in clinical development by year-end.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 5, 2026$2.39
est $2.30
+3.9%$493.0M
est $491.6M
+0.3%−20.5%
Aug 6, 2026$2.17
est $1.73
+25.4%$481.0M
est $402.3M
+19.6%+23.4%
May 11, 2026$1.22
est $1.76
−30.6%$376.7M
est $358.6M
+5.0%+10.6%
Feb 17, 2026−$0.24
est $2.20
−110.9%$451.8M
est $435.7M
+3.7%−7.8%
Nov 3, 2025$1.72
est $1.63
+5.5%$354.3M
est $446.5M
−20.7%+4.4%
Aug 5, 2025$1.54
est $1.23
+25.2%$325.7M
est $330.8M
−1.5%+3.9%
May 6, 2025$1.11
est $0.95
+16.8%$264.9M
est $281.0M
−5.7%+15.7%
Feb 18, 2025$1.26
est $1.16
+8.7%$298.0M
est $285.7M
+4.3%−0.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Halozyme Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Halozyme Therapeutics is $119.89, +19.6% from the last close, from 7 firms rating the stock in the last 90 days.

$119.89consensus 12-month target, +19.6% from the last close
Low $79High $149
Buy3
Hold4
Sell0

Each firm’s latest rating in the last 90 days: 7 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Morgan StanleyHold, downgraded$109+8.7%
Nov 6Wells FargoHold, reiterated$110+9.7%
Nov 6Leerink PartnersHold, downgraded$117+16.7%
Nov 6Citizens JMPBuy, maintained$149+48.6%
Nov 6H.C. WainwrightBuy, reiterated$130+29.6%
+11.8%average 20-day move after past Buying readings
−4.6%average move over the next 20 trading days in the last 5 years
±5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Halozyme Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Halozyme Therapeutics averaged −4.6% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−9.3%2021+9.3%2022+4.5%2023−11.0%2024−9.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−6.6%1 of 5
Next 10 trading days−6.5%1 of 5
Next 15 trading days−7.9%1 of 5
Next 20 trading days−4.6%2 of 5
Next 30 trading days−3.6%2 of 5

For scale, HALO’s typical 20-trading-day move in either direction is about 8.7%.

Halozyme Therapeutics market cap and key statistics

Halozyme Therapeutics’s market cap is $11.43B, with a P/E ratio of 25.2 and revenue of $1.80B over the last twelve months.

Valuation

Market cap
$11.43B
P/E ratio
25.2
Forward P/E
11.2
EPS, TTM
$4.00
Gekko Fair Value
$106.84

Trading

Volume
2.28M
Avg volume, 20 days
2.33M
52-week high
$134.00
52-week low
$61.23
Shares outstanding
114.0M

Financials

Revenue, TTM
$1.80B
Profit margin
26.9%
Return on equity
216.4%
Quarterly earnings growth, YoY
+40.6%

Risk and income

Beta
0.90
Typical daily move
±5%
Typical 20-day move
±8.7%

Halozyme Therapeutics stock news this week

Coverage of Halozyme Therapeutics this week reads negative: 5 positive, 1 neutral and 6 negative headlines.

News sentiment negative

Halozyme Therapeutics peers

Halozyme Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Halozyme Therapeutics stock FAQ

What is Halozyme Therapeutics’s market cap?

Halozyme Therapeutics’s market cap is $11.43B at the Nov 13, 2026 close of $100.27, with 114.0M shares outstanding. The shares trade on a P/E ratio of 25.2.

What is the Halozyme Therapeutics stock forecast?

The consensus analyst 12-month price target for Halozyme Therapeutics is $119.89, +19.6% from the last close. Of the 7 firms that rated the stock in the last 90 days, 3 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Halozyme Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Halozyme Therapeutics is undervalued: the Nov 13, 2026 close of $100.27 is 6.1% below Gekko Fair Value of $106.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Halozyme Therapeutics report earnings next?

Halozyme Therapeutics is expected to report on Feb 16, 2027, after the market closes (93 days away). Analysts expect earnings of $2.57 per share on revenue of $551.4M. Halozyme Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 10.9% on average across the report.

What is Halozyme Therapeutics’s 52-week high and low?

Halozyme Therapeutics’s 52-week high is $134.00 and its 52-week low is $61.23; it closed at $100.27 on Nov 13, 2026, +42.0% over the past year.

Is Halozyme Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Halozyme Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.